The effect of reexamination after lung cancer operation

summary

Some time ago, an elder of my family suffered from lung cancer, so the whole family has been cooperating with each other for treatment. I often go to the hospital to take care of him. After a long time, I have some understanding of his condition. Today, let me talk about the effect of reexamination after lung cancer surgery.

The effect of reexamination after lung cancer operation

First: one month after operation, chest CT, blood routine, liver and kidney function and tumor markers were reviewed. Chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland) and tumor markers were reviewed every 3-6 months within 2 years after operation. Six months later, chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. 9 months, chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), tumor markers. At 12 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. At 15 months, chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland) and tumor markers were detected. At 18 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. 21 months, chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), tumor markers.

Second: chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT) and tumor markers were reexamined every six months 2-5 years after operation. At 30 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. At 36 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. At 42 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. At 48 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers. In 54 months, chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers.

Third: chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT) and tumor markers were reexamined every year for more than 60 months after operation. At 72 months, chest CT, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers.

matters needing attention

The use of tumor markers can not only make differential diagnosis of lung cancer tissue types, make appropriate treatment plans for patients faster, but also monitor the treatment process of lung cancer patients, determine whether the treatment plan is effective and whether it needs to be replaced in time, detect tumor recurrence and metastasis early, effectively reduce the mortality rate of patients and reduce medical costs.